Table 2 SARS-CoV-2 variants considered in threshold analysis

Study	WHO SARS-CoV-2 name	Pango lineage (Hedgehog)^a	In vitro IC₅₀ (ng/mL)
PROVENT	Alpha	B.1.1.7	2.1
	Beta	B.1.351	5.6
	Wuhan	–	2.2
	BA.1	B.1.1.529.1	171.1
	BA.2	B.1.1.529.2	9.8
	Delta	B.1.617.2	2.2
	BA.1.1	B.1.1.529.1.1	466.0
	Eta	B.1.525	9.5
	Gamma	P.1	1.3
	Kappa	B.1.617.1	1.9
	Lambda	C.37	1.2
	Mu	B.1.621	17.2
	BA.4/5	B.1.1.529.4	69.4
	Iota	B.1.526	3.3
	Zeta	P.2	5.4
	Epsilon	B.1.427/B.1.429	1.3
SUPERNOVA	Omicron	BA.4 (B.1.1.529_1)	4.7
		BA.2 (B.1.1.529_2)	10.7
		XBB.1 (B.1.1.529_3)^b	3.6
		FL.1.5.1 (B.1.1.529_6)^c	1000
		BA.1.1 (BA.1.1_1)	4.6
		BA.1 (BA.1_1)	5.4
		BA.2.12.1 (BA.2.12.1_1)	7.9
		JF.1 (BA.2_21)^c	1000
		HV.1 (BA.2_22)^c	1000
		HK.3 (BA.2_3)^c	1000
		BA.2.75 (BA.2.75)	25
		BA.2.86 (BA.2.86_1)	3.8
		XBB.1.5 (BA.2_1)^b	5.8
		EG.5.1 (BA.2_2, BA.2_8)^c	1000
		EG.5 (BA.2_49, FE.1.1.3, FL.19.1)^c	1000
		JN.1 (BA.2_4)	83.1
		XBB.2.3.2 (BA.2_44)^b	5.6
		XBB (BA.2_5)^b	3.8
		GW.5 (BA.2_6)^c	1000
		GK.1 (BA.2_7)^c	1000
		JD.1.1 (BA.2_10)^c	1000
		BA.2.75.2 (BA.2_9)	9.7
		BA.4.6 (BA.4.6_1)	14.5
		BA.5.9 (BA.5.9)	4.7
		BF.7 (BA.5_1)	3.8
		BQ.1 (BA.5_2)	11.6
		BN.1 (BN.1_1, BN.1.2.5, BN.1.3.12)	8.3
		BN.1.3 (BN.1.3.3)	7.9
		BQ.1.3 (BQ.1.3_1)	13.4
		BQ.1.1 (BQ.1_1)	9.2
		BR.2 (BR.2_1)	21.2
		DV.7.1 (DV.7.1_1, DV.7.1.2)^c	1000
		XBB.1.16.1 (XBB.1.16.1_1)^b	6.3
		XBB.1.16.24 (XBB.1.16.24)^b	3
		XBB.1.5.1 (XBB.1.5.1)^b	4.6
		XBB.1.5.10 (XBB_2) ^b,c	1000
		XBB.1.19.1 (XBB.1_2)^b	4.5
		FD.2 (XBB.1_3)^b	4.5
		XBB.2.3.2 (XBB.2.3.2_1)^b	5.6
		XBB.2.3 (XBB.2.3_1)^b	3.4
		XBB.1.16 (XBB_1)^b	1.3
		Other with F456X mutation	1000^d
		Other with L455X mutation	83.1^d
		Other without L455X/ F456X mutations	7.1^d

The 16 variants considered for the PROVENT threshold analysis were those with ≥1% prevalence over follow-up and where in vitro IC₅₀ measurements were available (Monogram Biosciences).
The variants considered in the SUPERNOVA threshold analysis are those with ≥5% prevalence over follow-up.
IC₅₀ 50% inhibitory concentration, nAb neutralising antibody, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, WHO World Health Organisation.
^aHedgehog lineages are displayed for SUPERNOVA in brackets with one representative Pango lineage with available IC₅₀ shown for each hedgehog lineage. Due to Hedgehog utilising nucleotide sequences, some amino acid spike sequences tested for IC₅₀ may map to multiple hedgehog lineages.
^bThis family of variants is considered in subsequent XBB + subvariant analyses.
^cThese variants all contained an F456L mutation with IC₅₀ measured above the upper assay limit of 1000 ng/mL.
^dWhere IC₅₀ was not measured for a variant, variants with F456X and L455X mutations are imputed to a value of 1000 ng/mL (equal to the upper assay limit) and 83.1 ng/mL (consistent with JN.1), respectively, otherwise imputed to 7.1 ng/mL, which represents an average of known in vitro IC₅₀ values for sipavibart against variants that do not have either F456X or L455X mutations.

Search